Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02076295 · ClinicalTrials.gov registry record
Cholinergic Nicotinic Receptors and Cognition in PD
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 48
- Enrollment target
NCT02076295 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 48 participants.
The verdict
NCT02076295 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
Mild cognitive impairment and dementia are frequent non-motor complications of moderate to advanced Parkinson's disease. Brain positron emission tomography (PET) study findings confirm post-mortem evidence that cholinergic loss is related to cognitive impairment in Parkinson's disease. However, current cholinergic augmentation therapy is not always effective and it should only target those Parkinson's disease patients who have evidence of cholinergic system impairment. The objective of this study is to study the association of a particular subtype of cholinergic receptors, so-called nicotinic acetylcholine receptors, with cognition in Parkinson's disease using a novel PET marker of cholinergic system integrity.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02076295
The ClinicalTrials.gov registry entry for NCT02076295 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02076295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02076295 about?
NCT02076295 is a clinical study titled "Cholinergic Nicotinic Receptors and Cognition in PD". Mild cognitive impairment and dementia are frequent non-motor complications of moderate to advanced Parkinson's disease. Brain positron emission tomography (PET) study findings confirm post-mortem evidence that cholinergic loss is related to cognitive impairment in Parkinson's disease. However, curr...
What is the current status of trial NCT02076295?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2014-02. Estimated completion is 2016-12-30.
Who is sponsoring clinical trial NCT02076295?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.